France CAR-T Cell Therapy Market Anticipates Impressive Growth Amid Advances in Personalized Medicine and Increase in Hematological Malignancies
12 févr. 2024 04h32 HE
|
Research and Markets
Dublin, Feb. 12, 2024 (GLOBE NEWSWIRE) -- The "France CAR-T Cell Therapy Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ...
Autolus Announces Pricing of Underwritten Offering
08 févr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Announces Pricing of Underwritten Offering
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
08 févr. 2024 05h45 HE
|
Autolus Therapeutics plc; BioNTech SE
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical Recognition, and Fast Track Designation Regulatory Approvals
24 janv. 2024 14h23 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With the...
Global CAR T-Cell Therapy Research Report 2023: Market Poised for Substantial Growth by 2030, Driven by Advancements in Cancer Treatment and Increasing Incidence Rates
24 janv. 2024 04h13 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global CAR T-Cell Therapy Market 2030 by Drug type, Indication, Target Antigen, End-user and Region - Partner & Customer Ecosystem Competitive...
Autolus Therapeutics announces publication in ACS Chemical Biology
23 janv. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces publication in ACS Chemical Biology
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
22 janv. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL
Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
16 janv. 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
10 janv. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Monthly information on share capital and company voting rights
08 janv. 2024 16h30 HE
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...